PLEASANTON, CA--(MARKET WIRE)--Jun 7, 2007 -- Lipid Sciences, Inc. (NasdaqGM:LIPD - News) -- At the Company’s Annual Meeting of Stockholders, President and Chief Executive Officer, Dr. S. Lewis Meyer, announced that the Company has developed a synthetic form of HDL that mimics key functions of naturally-occurring human HDL. The Company’s lead HDL Mimetic Peptide compound, LSI 518P, and a back-up compound have been identified and validated with an extensive battery of in vitro assays. The lead compound was selected as a result of screenings at multiple sites: The Baker Institute, Melbourne, Australia; the Children’s Hospital of Philadelphia; and in Lipid Sciences’ own laboratory. In these tests, the selected mimetic peptide candidates effluxed cholesterol via the ABCA1 transporter metabolic pathway -- known to be optimal for removing cholesterol from arterial plaque via the reverse cholesterol transport mechanism -- at a rate similar to naturally-occurring HDL. Dr. Meyer noted that the Company’s “synthetic HDL” should not only enhance reverse cholesterol transport, but also mimic the other important biological functions of HDL -- contribution to plaque regression and reduction the inflammation associated with atherosclerosis.
